Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.67+0.15 (+0.49%)
Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%
Pfizer Pfizer Ignite [legacy through Q4 2025] by Year
Pfizer Ignite (end-to-end biotech R&D services) [legacy through Q4 2025] ($M) ($M)
Pfizer Pfizer Ignite [legacy through Q4 2025]: $41M in FY2025, down 50.0% from a year earlier.
Latest, FY2025
41
Period ended Dec 31, 2025
Change on a year earlier
-50.0%
82 in FY2024
History
5 years
Since FY2021
Sources
3
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-26) ↗
Reported in Form 10-K Segment Note.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Pfizer Ignite (end-to-end biotech R&D services) [legacy through Q4 2025] ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 41 | -50.0% | Form 10-K (filed 2026-02-26) ↗ |
| FY2024 | Dec 31, 2024 | 82 | +86.4% | Form 10-K (filed 2026-02-26) ↗ |
| FY2023 | Dec 31, 2023 | 44 | +528.6% | Form 10-K (filed 2026-02-26) ↗ |
| FY2022 | Dec 31, 2022 | 7 | – | Form 10-K (filed 2025-02-27) ↗ |
| FY2021 | Dec 31, 2021 | 0 | – | Form 10-K (filed 2024-02-22) ↗ |
Cite this data
StockData. (2026). Pfizer Pfizer Ignite [legacy through Q4 2025] ($M), annual FY2021–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/pfizer-ignite-leg
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.